Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biotricity Inc (BTCY)
OTHER OTC:BTCY
Holding BTCY?
Track your performance easily
Earnings Data
Report Date
Feb 18, 2025TBA Not Confirmed
Period Ending
2025 (Q3)Consensus EPS Forecast
-$0.11Last Year’s EPS
-$0.34Same Quarter Last Year
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 15, 2024
|% Change Since: -30.00%
|Next Earnings Date:Feb 18, 2025
Earnings Call Sentiment|Positive
The earnings call presents a predominantly positive outlook with significant achievements in EBITDA, revenue growth, strategic partnerships, and market expansion. Despite the continued net loss, the improvements and strategic advancements position Biotricity well for future profitability.Company Guidance
During the Q2 2025 earnings call for Biotricity (BTCY), management provided optimistic guidance marked by impressive financial metrics and strategic advancements. The company achieved a 13% year-over-year increase in revenue, reaching $3.3 million, and improved gross profit by 23% to $2.5 million. Operating expenses decreased by 34%, contributing to a 57% reduction in net loss to $1.65 million. Biotricity reported its first-ever positive EBITDA in September, with EBITDA and adjusted EBITDA improving by 80% and 87% respectively over the previous year. The strategic focus on expanding partnerships, particularly with group purchasing organizations (GPOs), has enabled access to over 90% of U.S. hospitals, facilitating larger sales opportunities. Additionally, the company has made significant strides in reducing selling, general, and administrative expenses by 35.5% and R&D expenses by almost 26%. Looking ahead, Biotricity aims to leverage its robust inventory and strategic alliances to drive sustained growth and profitability in the cardiac care market.Achievement of Positive EBITDA
Biotricity achieved positive EBITDA for the first time in September 2025, marking a significant milestone in their path to profitability.
Revenue Growth
Revenue increased by 13% year-over-year to $3.3 million for the second quarter ended September 30, 2025.
Transition to Flat Fee Model
Biotricity successfully transitioned approximately 75% of their business to a flat fee subscription model, resulting in a 34% year-over-year growth in flat fee revenue.
Gross Profit Improvement
Gross profit for the quarter totaled $2.5 million, up 23% from $2 million in the prior year period, with a gross profit percentage improvement by 1,468 basis points to 75.3%.
Reduction in Operating Expenses
Operating expenses for the second quarter of fiscal 2025 were $2.8 million, a 34% improvement from the previous year, with SG&A expenses decreasing by 35.5%.
Strategic Partnerships and Market Expansion
Biotricity formed strategic alliances with top GPOs and specialist organizations in neurology and pulmonology, expanding their market reach beyond cardiology.
Significant Inventory Procurement
The company placed the largest inventory order in its history, indicating strong confidence in future growth and a clear path to profitability.
International Expansion
Biotricity received approvals from regulatory bodies in other countries, including Canada, allowing them to sell in new jurisdictions.
---
BTCY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
BTCY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 15, 2024 | $0.40 | $0.45 | +12.50% |
| Aug 21, 2024 | $0.48 | $0.42 | -12.50% |
| Jun 27, 2024 | $0.87 | $0.93 | +6.90% |
| Feb 21, 2024 | $1.17 | $1.22 | +4.27% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Biotricity Inc (BTCY) report earnings?
Biotricity Inc (BTCY) is schdueled to report earning on Feb 18, 2025, TBA Not Confirmed.
What is Biotricity Inc (BTCY) earnings time?
Biotricity Inc (BTCY) earnings time is at Feb 18, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BTCY EPS forecast?
BTCY EPS forecast for the fiscal quarter 2025 (Q3) is -$0.11.
---